A	O
Microfluidic	O
Platform	O
to	O
design	O
crosslinked	O
Hyaluronic	O
Acid	O
Nanoparticles	O
(	O
cHANPs	O
)	O
for	O
enhanced	B:C1707501
MRI	I:C1707501
.	O

Recent	O
advancements	O
in	O
imaging	B:C0011923
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	O
Agents	I:C0009924
(	O
Contrast	O
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Recent	O
advancements	O
in	O
imaging	O
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	B:C0024485
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	O
Agents	I:C0009924
(	O
Contrast	O
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Recent	O
advancements	O
in	O
imaging	O
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	B:C0024485
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	O
Agents	I:C0009924
(	O
Contrast	O
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Recent	O
advancements	O
in	O
imaging	O
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	B:C0009924
Agents	I:C0009924
(	O
Contrast	O
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Recent	O
advancements	O
in	O
imaging	O
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	O
Agents	I:C0009924
(	O
Contrast	B:C0009924
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Recent	O
advancements	O
in	O
imaging	O
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	O
Agents	I:C0009924
(	O
Contrast	O
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	B:C0220806
modify	O
the	O
clinically	O
approved	O
compounds	O
.	O

Recent	O
advancements	O
in	O
imaging	O
diagnostics	I:C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
(	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
)	O
Contrast	O
Agents	I:C0009924
(	O
Contrast	O
Agents	I:C0009924
)	O
,	O
without	O
the	O
need	O
to	O
chemically	O
modify	O
the	O
clinically	O
approved	O
compounds	B:C1706082
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
Magnetic	B:C0024485
Resonance	I:C0024485
Imaging	I:C0024485
-	O
Contrast	O
Agents	I:C0009924
,	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
(	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
)	O
,	O
is	O
entrapped	O
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
-	O
Contrast	B:C0009924
Agents	I:C0009924
,	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
(	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
)	O
,	O
is	O
entrapped	O
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
-	O
Contrast	O
Agents	I:C0009924
,	O
gadolinium	B:C0060933
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
(	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
)	O
,	O
is	O
entrapped	O
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
-	O
Contrast	O
Agents	I:C0009924
,	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
(	O
gadolinium	B:C0060933
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
)	O
,	O
is	O
entrapped	O
.	O

Furthermore	O
,	O
the	O
interference	O
of	O
gadolinium	B:C0060933
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
during	O
polymer	O
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic	O
-	O
lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	O
and	O
pH	O
conditions	O
.	O

Furthermore	O
,	O
the	O
interference	O
of	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
during	O
polymer	B:C0032521
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic	O
-	O
lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	O
and	O
pH	O
conditions	O
.	O

Furthermore	O
,	O
the	O
interference	O
of	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
during	O
polymer	O
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic	O
-	O
lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	B:C0038891
and	O
pH	O
conditions	O
.	O

For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	B:C0060933
-	O
loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	O
-	O
loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
in	O
solution	O
.	O

For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	O
-	O
loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	B:C0060933
-	O
loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
gadolinium	O
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
in	O
solution	O
.	O

For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	O
-	O
loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	O
-	O
loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
gadolinium	B:C0060933
diethylenetriamine	I:C0060933
penta-acetic	I:C0060933
acid	I:C0060933
in	O
solution	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	B:C0442123
-	O
injectable	O
and	O
completely	O
biocompatible	O
hydrogel	I:C0063083
nanoparticles	O
entrapping	O
clinically	O
approved	O
Contrast	O
Agents	I:C0009924
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	O
applications	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	B:C1272883
and	O
completely	O
biocompatible	O
hydrogel	I:C0063083
nanoparticles	O
entrapping	O
clinically	O
approved	O
Contrast	O
Agents	I:C0009924
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	O
applications	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	O
and	O
completely	O
biocompatible	B:C0063083
hydrogel	I:C0063083
nanoparticles	O
entrapping	O
clinically	O
approved	O
Contrast	O
Agents	I:C0009924
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	O
applications	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	O
and	O
completely	O
biocompatible	O
hydrogel	I:C0063083
nanoparticles	O
entrapping	O
clinically	O
approved	O
Contrast	B:C0009924
Agents	I:C0009924
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	O
applications	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	O
-	O
injectable	O
and	O
completely	O
biocompatible	O
hydrogel	I:C0063083
nanoparticles	O
entrapping	O
clinically	O
approved	O
Contrast	O
Agents	I:C0009924
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	B:C0087111
applications	O
.	O

